Trials / Completed
CompletedNCT01843855
The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Adrian Vella · Academic / Other
- Sex
- All
- Age
- 20 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The study is being undertaken to understand how a gastric bypass can affect a subject's diabetes even prior to their losing significant amounts of weight. The hypothesis of this study is that increased glucagon-like peptide-1 (GLP-1) secretion explains the amelioration in insulin secretion after Roux-en-Y Gastric Bypass (RYGB) surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Exendin 9,39 | Exendin 9,39 is a competitive antagonist of endogenous GLP-1. |
| DRUG | Placebo | A saline infusion will be given to match the study drug infusion. |
Timeline
- Start date
- 2011-06-01
- Primary completion
- 2013-07-01
- Completion
- 2013-09-01
- First posted
- 2013-05-01
- Last updated
- 2013-12-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01843855. Inclusion in this directory is not an endorsement.